EDEN PRAIRIE, Minn., July 05, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ:MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, applauds the U.S. Food and Drug Administration (FDA) for hosting a two-day public advisory committee meeting to discuss scientific and regulatory topics relating to the field of organ transplant, specifically xenotransplantation. Opening remarks from the FDA highlighted the limited availability of human organs for transplant and recognized the tremendous unmet need for new treatments for patients with end-stage organ failure.
Miromatrix Applauds the FDA for Its Continued Commitment to the Field of Organ Transplant
Globe Newswire -
Tue Jul 5, 2022
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Tesla%20charging%20station%20black%20background%20by%20Blomst%20via%20Pixabay.jpg)
/Netflix%20on%20laptop%20by%20Jade87%20via%20Pixabay.jpg)
